Literature DB >> 24935330

The protective effect of huperzine A against hepatic ischemia reperfusion injury in mice.

Y Yang1, J Yang2, Q Jiang2.   

Abstract

BACKGROUND: Nowadays, hepatic ischemia reperfusion (HI/R) injury is regarded as a serious concern in clinical practices. Huperzine A (HupA) is an alkaloid isolated from the Chinese folk medicine huperzia serrate, which has possessed diverse pharmacological actions.
METHODS: A mouse model of HI/R was caused by clamping the hepatic artery, the hepatoportal vein, and the bile duct with a vascular clamp for 30 minutes followed by reperfusion for 6 hours under anesthesia. The sham group experienced the identical procedure without hepatic ischemia. The HupA group received an injection into the tail vein 5 minutes prior to HI/R at the doses of 167 and 500 μg/kg. The vehicle group was injected with physiological saline instead of HupA. The liver function was assessed by determinations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities. Tissue levels of superoxide dismutase (SOD), catalase (CAT), malondiadehyde (MDA), and glutathione (GSH) were also measured spectrophotometrically. In addition, the activities of hepatic inflammatory mediators such as nuclear factor kappa B (NF-κB) p65, tumor necrosis factors-α (TNF-α, interleukin-1β (IL-1β) and IL-6 were also measured. Furthermore, the apoptotic damage was evaluated by measuring caspase-3 activity in hepatic tissues.
RESULTS: Treatment with HupA in mice at the doses of 167 and 500 μg/kg remarkably reduced serum ALT and AST activities in HupA-treated ischemic mice. Furthermore, HupA treatment could enhance the activities of hepatic tissue SOD, CAT, and GSH but decrease MDA tissue content. The activities of inflammatory cytokines including NF-κB p65, TNF-α, IL-1β and IL-6 were all decreased in ischemic mice treated with HupA. Colorimetric test results illustrated that a marked reduction of caspase-3 activity was found in the HupA-treated group compared with the vehicle group.
CONCLUSION: Our present data suggest that HupA has a protective role against HI/R injury of mice and antioxidative, anti-inflammatory, and antiapoptotic actions are involved in its protection.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935330     DOI: 10.1016/j.transproceed.2014.01.018

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Preventive activity of banana peel polyphenols on CCl4-induced experimental hepatic injury in Kunming mice.

Authors:  Rui Wang; Xia Feng; Kai Zhu; Xin Zhao; Huayi Suo
Journal:  Exp Ther Med       Date:  2016-03-11       Impact factor: 2.447

2.  Huperzine A inhibits immediate addictive behavior but not behavioral sensitization following repeated morphine administration in rats.

Authors:  Jinling Sun; Lin Tian; Ruisi Cui; Xinwang Li
Journal:  Exp Ther Med       Date:  2017-02-02       Impact factor: 2.447

Review 3.  A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.

Authors:  Mayuri Shukla; Prapimpun Wongchitrat; Piyarat Govitrapong
Journal:  Neurochem Res       Date:  2022-02-05       Impact factor: 3.996

4.  Pan-caspase inhibitor F573 mitigates liver ischemia reperfusion injury in a murine model.

Authors:  Mariusz Bral; Rena Pawlick; Braulio Marfil-Garza; Nidheesh Dadheech; Joshua Hefler; Aducio Thiesen; A M James Shapiro
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

5.  PPAR-gamma activation is associated with reduced liver ischemia-reperfusion injury and altered tissue-resident macrophages polarization in a mouse model.

Authors:  Ivan Linares; Kaveh Farrokhi; Juan Echeverri; Johan Moritz Kaths; Dagmar Kollmann; Matyas Hamar; Peter Urbanellis; Sujani Ganesh; Oyedele A Adeyi; Paul Yip; Markus Selzner; Nazia Selzner
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.